Abstract: The present invention discloses a novel composition of the elution mobile phase for virus purification by immunoaffinity chromatography which is consisting of one or more amino acids: L-serine, L-asparagine, or L-glutamine, or their salts with pharmaceutically acceptable acids; one or more auxiliary ingredients: L-arginine, glycine or imidazole, or their salts with pharmaceutically acceptable acids; one or more pharmaceutically acceptable pH adjusting agents for correcting the pH value of the mobile phase from pH=6.0-8.0; and purified water, up to 100% w/w of the mobile phase composition. The invention provides the use of immunoaffinity chromatography as a key step in the production of viral vaccines and/or viral vectors, in separation of infectious from non-infectious viral particles, and for enrichment of the viral suspension in infectious viral particles.

Abstract: The present invention discloses a novel composition of the elution mobile phase for virus purification by immunoaffinity chromatography which is consisting of one or more amino acids: L-serine, L-asparagine, or L-glutamine, or their salts with pharmaceutically acceptable acids; one or more auxiliary ingredients: L-arginine, glycine or imidazole, or their salts with pharmaceutiacally acceptable acids; one or more pharmaceutically acceptable pH adjusting agents for correcting the pH value of the mobile phase from pH=6.0-8.0; and purified water, up to 100% w/w of the mobile phase composition. The invention provides the use of immunoaffinity chromatography as a key step in the production of viral vaccines and/or viral vectors, in separation of infectious from non-infectious viral particles, and for enrichment of the viral suspension in infectios viral particles.